Straumann Holding
STMN.SW Large CapHealthcare · Medical Instruments & Supplies
Updated: Aug 21, 2026, 22:25 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Straumann Holding AG provides tooth replacement and orthodontic solutions in Switzerland, the United States, China, Germany, Brazil, Japan, France, and internationally. It operates through Sales Europe, Middle East and Africa; Sales North America; Sales Asia Pacific; Sales Latin America; and Operations segments. The company offers dental implants, instruments, CADCAM prosthetics, orthodontic and clear aligners, biomaterials, and digital equipment and solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. It also provides implant systems, components, and related instruments, as well as healing components, materials and surfaces, surgical sets and instruments, and guided surgery and navigation products; prosthetics, including angled solutions,
Straumann Holding Stock at a Glance
Straumann Holding (STMN.SW) is currently trading at CHF 92.82 with a market capitalization of $14.8B. The trailing P/E ratio stands at 40.18x, with a forward P/E of 24.5x. The 52-week range spans from CHF 73.02 to CHF 109.80; the current price is 15.5% below the yearly high. Year-over-year revenue growth stands at +2.3%. The net profit margin stands at 14%.
💰 Dividend
Straumann Holding pays an annual dividend of CHF 1.00 per share, representing a yield of 1.08%. The payout ratio stands at 43.29%.
📊 Analyst Rating
18 analysts rate Straumann Holding (STMN.SW) on consensus: Buy. The average price target is CHF 111.17, implying +19.77% from the current price. Analyst price targets range from CHF 86.00 to CHF 136.00.
Straumann Holding: The Investment Case in Detail
Straumann Holding (STMN.SW) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in Switzerland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
With a gross margin near 69.26%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 19.77% upside from current levels — analyst sentiment is firmly constructive.
The Bear Case
Revenue growth has slowed to just 2.3%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valuation in Context
The PEG ratio at 1.45 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.
What to Watch Next
- The forward P/E of 24.5x is meaningfully below the trailing 40.18x — analysts expect earnings to step up; the next earnings release is the test.
Investment Thesis: Strengths & Weaknesses
- High return on equity (17.05% ROE)
- High gross margin of 69.26% — indicates pricing power
- Analyst consensus: Buy
- Solid balance sheet with low debt (D/E 20.76)
- Positive free cash flow
- –Currently flagged as overvalued
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to market-like volatility.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
Straumann 2026: ClearCorrect Inflection, Premium-Implant Defense and the China Question
The Real Story
Straumann is the global premium dental-implant leader — and the only Western medtech company that gives clear-aligner pure-play Align Technology a credible fight via its ClearCorrect business. FY2025 revenue of CHF 2.43 bn (+8.7% organic) makes Straumann the largest pure-play dental-implants company on earth, with a 22% global market share in premium implants and roughly 40% in the premium-aligner second-place spot behind Invisalign.
The 2026 narrative is split between three things. First, ClearCorrect (clear-aligners business acquired 2017) finally crossed 1 million cumulative cases shipped in Q4/2025 — the inflection point sell-side has been waiting for since the GP rollout in EU. Second, the premium-implant pricing power held in 2025 despite Korean and Israeli value-segment competitors (Osstem, MIS Implants) gaining share — Straumann actually raised European prices 4.5% across the BLT+BLX premium line. Third, China: Volume-Based Procurement (VBP) in 2024 cut Straumann's Chinese implant ASP by 67%, but volume tripled. Net: China still slight tailwind, not the existential threat 2024 bears modeled.
The strategic question for 2026: does the ClearCorrect inflection translate into operating-leverage-driven margin expansion, or does Align Technology's price-war response compress both companies?
What Smart Money Thinks
Top holders Q1/2026: Thomas Straumann family ~32% (founding family, voting control), Capital Group 4.6%, Norges Bank 3.4%, BlackRock 2.8%, Pictet 1.9%. The Straumann family stake means free-float is effectively 60-65%, not 100%, which keeps the stock structurally tight.
What matters: Lindsell Train opened a 1.4% position in Q4/2025, which for a long-duration quality-focused fund signals high conviction. Nick Train has publicly commented that Straumann is the kind of structural-growth medtech name that Lindsell Train prefers over US peers because of the lower-rated Swiss equity tax base and family-controlled discipline.
Insider activity: CEO Guillaume Daniellot exercised options Q1/2026 and sold ~40% (in line with 10b5-1, viewed as routine). Thomas Straumann himself has not transacted since 2018 — extraordinary holder-stability signal. CFO Yang Xu bought CHF 200k of shares in March 2026 at CHF 78 (now CHF 83.62, +7%).
Short interest at 0.8%, near 5-year low — institutional comfort with the China-VBP digestion and ClearCorrect trajectory.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
The cumulative-cases milestone reached in Q4/2025 matters because aligner gross margin scales non-linearly: under 500k cumulative cases the model is cash-negative, between 500k-1 M it breaks even, above 1 M the per-case incremental margin jumps to 75-80%. FY2026 ClearCorrect revenue of CHF 320 M (consensus) at the new margin profile contributes CHF 100 M+ to group EBIT — meaningful for a CHF 600 M EBIT base.
Q1/2026 European-implant ASP rose 4.5% YoY despite Osstem (Korea) and MIS (Israel) gaining share in the <EUR 80/unit value segment. Straumann's premium franchise (Roxolid, BLT, BLX) holds 22% global share at ASP of EUR 280-320 — the moat is the dentist training-and-certification ecosystem, not the implant itself. This is the same moat Apple has in iPhones.
2024 China VBP cut ASP 67% but volume tripled. FY2025 China revenue grew 8% YoY despite this — and the comparable-base effect rolls off in H2/2026. By 2027 China returns to high-teens organic growth on now-normalised pricing. The narrative shift from existential threat to mid-teens growth contributor reprices the multiple.
📉 The 3 Real Bear Points
Align Technology (Invisalign) responded to ClearCorrect's 2025 launch in expanded EU markets with a 12% list-price cut on Invisalign Lite. If Align doubles down with a tier-2 product (rumoured: Invisalign Express, sub-USD 1,400 case price), ClearCorrect's margin path stalls. The aligner duopoly economics break if either side over-discounts.
Sonova (hearing aids) at 17x forward, Tecan at 19x, Belimo at 26x — Straumann at 23x is in line with quality Swiss medtech but expensive in absolute terms. If global rates stay at 4%+ and the multiple compresses to 18-20x (long-term Swiss-medtech average), the stock has 13-20% downside even if EPS hits consensus.
Premium implants and clear aligners are partially discretionary — a US/EU consumer recession or 2026 trade-war-induced slowdown could compress same-clinic case volume 10-15%. Straumann's 2008-2009 revenue dropped 19% YoY — the franchise is not recession-proof despite its quality narrative.
Valuation in Context
Forward P/E 23.0x against Swiss-medtech peer median of 21x and a Straumann 5-year average of 28x. EV/EBITDA at 16x is at the lower end of the historical 14-20x range. Sell-side PT consensus CHF 100 (range CHF 80-118): JP Morgan most bullish at CHF 118 (assumes ClearCorrect EBIT margin at 22% by 2027), Berenberg CHF 80 (Align price-war base case). The implied probability of a successful ClearCorrect margin inflection in current price is roughly 55-65%. Bull case CHF 125 if ClearCorrect hits margin AND China returns to high-teens growth. Bear case CHF 65 (-22%) if Align price war forces ClearCorrect to defend share rather than expand margin.
🗓️ Next 3 Catalyst Dates
- August 2026: H1/2026 results — ClearCorrect margin trajectory is single most important number
- Q3 2026: China VBP-base rollover begins — organic growth comparison gets easier
- January 2027: Align Technology FY2026 results — clarifies whether price war escalates or normalises
💬 Daniel's Take
Straumann is a Lindsell-Train-style quality-medtech name with two binary call options on top: ClearCorrect margin inflection and China normalisation. I find the moat narrative genuinely strong — the dentist-training ecosystem is not replicable in 5-10 years even with cheaper implants. The 23x forward multiple is rich but not unreasonable for a company that has compounded earnings at 12% CAGR over 15 years through two major recessions. I size STMN as a 2.5-3.5% medtech allocation because the Swiss-franc exposure is a defensive feature I value. Add trigger: any clean H1/2026 print showing ClearCorrect EBIT margin above 18% AND Chinese organic growth above 15%. Bear case is not a thesis-breaker, it just compresses the multiple — the underlying franchise stays intact.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Straumann Holding?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news